Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2023-12-12 00:00:00 ET · period of report 2023-12-08 · accession 0001968202-23-000051 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-12-12 | 2023-12-08+ | REGN | Landry Robert E | EVP Fin CFO | F - Tax | $844.02 | -4,234 | 30.0K | -12% | -$3.57M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-12-08 | F | D | 1,013 | $843.79 | 30,686 | D | — | — | |
| 2 | Common | Common Stock | 2023-12-11 | F | D | 2,552 | $844.09 | 27,465 | D | — | — | |
| 3 | Common | Common Stock | 2023-12-11 | F | D | 669 | $844.09 | 30,017 | D | — | — |